In addition, more clinical and translational data on irreversible EGFR inhibitors and dual targeted therapy in molecularly-selected subgroups of patients will help oncologists to personalize therapy of advanced NSCLC even further. This evidence concerns the gene EGFR and non-small cell lung carcinoma.